Press releases
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
- Karyopharm to Participate at the Jefferies Global Healthcare Conference
- Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
- Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
- Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
- Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
- Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
More ▼
Key statistics
As of last trade, Karyopharm Therapeutics Inc (25K:MUN) traded at 0.937, 44.60% above the 52 week low of 0.648 set on Nov 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.937 |
---|---|
High | 0.937 |
Low | 0.937 |
Bid | 0.8778 |
Offer | 0.955 |
Previous close | 0.937 |
Average volume | 2.17k |
---|---|
Shares outstanding | 117.71m |
Free float | 105.70m |
P/E (TTM) | -- |
Market cap | 112.59m USD |
EPS (TTM) | -1.28 USD |
Data delayed at least 15 minutes, as of Jun 18 2024 07:06 BST.
More ▼